Announcement on Convening 2023 3rd Quarter Performance Meeting
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
Announcement on Convening 2023 3rd Quarter Performance Meeting
Filed with SSE ·
Announcement on Convening 2023 3rd Quarter Performance Meeting
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
6ix hasn’t read this filing yet.
Earlier from BeOne Medicines
- Announcement on Voluntary Disclosure of National Institute for Health and Care Excellence's Recommendation of Baiyueze (Zanubrutinib Capsules) for Treatment of Adult Patients with Chronic Lymphocytic Leukemia
- Announcement on Voluntary Disclosure of Progress in Obtaining Positive Registration of Baize'an (Tislelizumab Injection) in Europe and America
Later from BeOne Medicines
- Announcement on Adjusting Investment Amount of Raised Funds Invested in Investment Subproject Financed by Raised Funds
- Announcement on Initial Public Offering of Restricted Shares under Strategic Allotment for Circulation
- Announcement on Signing Consulting Agreement and Related Transaction
- Announcement on 2023 Annual Preliminary Earnings Estimate
- Announcement on Progress in Joint Investment with Related Party and Related Transaction
Follow BeOne Medicines into a list and get an email when it puts out news.
Follow BeOne Medicines